|
At present, GENEPHARM has
successfully developed two major technology platforms,
Calcium-T and Aero-Foli, that can be widely used in various
types of topical applications, such as:
1) skin care;
2) pre- and post-cosmetic procedures;
3) adjuvant therapy; and
4) prescription & OTC drugs.
The business approaches are:
-
For skin care, cosmeceutical and other mass markets
 Brand Creation: DERMESIS
DERMESIS is suitable for speeding up the epidermal barrier recovery after cosmetic procedures, such as microdermabration, photofacial, laser resurfacing, chemical peel and thermage. DERMESIS entered the market through various accesses such as academic meetings, physician visits and other forms of promotions in different countries and regions.
Technology licensing
GENEPHARM and
NICE Enterprises (Taiwan) co-develop new skin care products
such as facial mask, cleanser, body mist and cream, etc. The
products will be launched in 2008.
-
For adjuvant therapy, OTC and prescription drugs
Technology alliance
GENEPHARM and the first listed Japanese biotechnology company AnGes MG conducted collaborative research and increased the skin penetration rate of large drug molecules nearly 10 times, using the patented Gel-pad technology.
Technology Transfer
Aero-Foli
technology platform is now authorized and
transferred to Quiver (Taiwan). Under the guidance of
GENEPHARM, Quiver has successfully developed three OTC products and four topical prescription drugs.
¡@ |
